Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.

Patel H, Munir K, Sutherland S, Karanikas CA, Konig M

Diabetes therapy : research, treatment and education of diabetes and related disorders11 Oct 2019Cited by 7 (Europe PMC)

PMID31605302PMCIDPMC6848683DOI10.1007/s13300-019-00709-9PepBankPUB-31605302

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In T2D patients receiving background oral therapy, dulaglutide reduced HbA1c from baseline across regimen groups.
In plain wordsIn T2D patients receiving background oral drugs, HbA1c fell after dulaglutide across regimen groups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c change
Study
n = 1,784
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
HbA1c change
−1.3 to −1.6%
range across background regimens
Source sentences
Summary
At 6 months, the addition of once-weekly dulaglutide 1.5 mg to various OH regimens significantly reduced HbA1c (- 1.3 to - 1.6%) and fasting blood glucose (- 29 to - 45 mg/dl) from baseline in all groups (p < 0.001), with 39-61% and 52-76% of these patients achieving HbA1c targets of ≤ 6.5% and < 7%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530201
02HumanObservational studyEfficacy outcome
In T2D patients receiving background oral therapy, dulaglutide reduced fasting blood glucose from baseline across regimen groups.
In plain wordsIn T2D patients receiving background oral drugs, fasting blood glucose fell after dulaglutide across regimen groups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseFasting blood glucose change
Study
n = 1,784
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
Fasting glucose change
−29 to −45 mg/dl
range across background regimens
Source sentences
Summary
At 6 months, the addition of once-weekly dulaglutide 1.5 mg to various OH regimens significantly reduced HbA1c (- 1.3 to - 1.6%) and fasting blood glucose (- 29 to - 45 mg/dl) from baseline in all groups (p < 0.001), with 39-61% and 52-76% of these patients achieving HbA1c targets of ≤ 6.5% and < 7%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530202
03HumanObservational studyEfficacy outcome
In T2D patients receiving background oral therapy, 39-61% achieved HbA1c at or below 6.5% after dulaglutide.
In plain wordsIn T2D patients receiving background oral drugs, 39-61% achieved HbA1c at or below 6.5% after dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c at or below 6.5%
Study
n = 1,784
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
HbA1c target attainment
39 to 61%
HbA1c ≤6.5% across background regimens
Source sentences
Summary
At 6 months, the addition of once-weekly dulaglutide 1.5 mg to various OH regimens significantly reduced HbA1c (- 1.3 to - 1.6%) and fasting blood glucose (- 29 to - 45 mg/dl) from baseline in all groups (p < 0.001), with 39-61% and 52-76% of these patients achieving HbA1c targets of ≤ 6.5% and < 7%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530203
04HumanObservational studyEfficacy outcome
In T2D patients receiving background oral therapy, 52-76% achieved HbA1c below 7% after dulaglutide.
In plain wordsIn T2D patients receiving background oral drugs, 52-76% achieved HbA1c below 7% after dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableHbA1c below 7%
Study
n = 1,784
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
HbA1c target attainment
52 to 76%
HbA1c <7% across background regimens
Source sentences
Summary
At 6 months, the addition of once-weekly dulaglutide 1.5 mg to various OH regimens significantly reduced HbA1c (- 1.3 to - 1.6%) and fasting blood glucose (- 29 to - 45 mg/dl) from baseline in all groups (p < 0.001), with 39-61% and 52-76% of these patients achieving HbA1c targets of ≤ 6.5% and < 7%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530204
05HumanObservational studyEfficacy outcome
In T2D patients receiving background oral therapy, dulaglutide reduced body weight from baseline across regimen groups.
In plain wordsIn T2D patients receiving background oral drugs, body weight fell after dulaglutide across regimen groups.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n = 1,784
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
Weight change
−0.8 to −2.9 kg
range across background regimens
Source sentences
Summary
Significant reductions in body weight (- 0.8 to - 2.9 kg) were also observed in all groups (p < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530205
06HumanObservational studySafety outcome
In T2D patients receiving background oral therapy, nausea occurred in 10-35% after dulaglutide across regimen groups.
In plain wordsIn T2D patients receiving background oral drugs, 10-35% reported nausea after dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableNausea
Study
n = 1,784
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
Nausea
10 to 35%
range across background regimens
Source sentences
Summary
Nausea, vomiting, and diarrhea were reported by 10-35%, 4-19%, and 6-28% of patients, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530206
07HumanObservational studySafety outcome
In T2D patients receiving background oral therapy, vomiting occurred in 4-19% after dulaglutide across regimen groups.
In plain wordsIn T2D patients receiving background oral drugs, 4-19% reported vomiting after dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableVomiting
Study
n = 1,784
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
Vomiting
4 to 19%
range across background regimens
Source sentences
Summary
Nausea, vomiting, and diarrhea were reported by 10-35%, 4-19%, and 6-28% of patients, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530207
08HumanObservational studySafety outcome
In T2D patients receiving background oral therapy, diarrhea occurred in 6-28% after dulaglutide across regimen groups.
In plain wordsIn T2D patients receiving background oral drugs, 6-28% reported diarrhea after dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiarrhea
Study
n = 1,784
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
Diarrhea
6 to 28%
range across background regimens
Source sentences
Summary
Nausea, vomiting, and diarrhea were reported by 10-35%, 4-19%, and 6-28% of patients, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530208
09HumanObservational studySafety outcome
In T2D patients receiving dulaglutide, severe hypoglycemia occurred in one patient receiving background metformin and sulfonylurea.
In plain wordsIn T2D patients receiving dulaglutide, one patient receiving metformin and sulfonylurea had severe low blood sugar.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSevere hypoglycemia
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.5 mg once weekly · 6 monthsAs given in this study (human).
Measurements
Severe hypoglycemia
1 patient
MET + SU background
Source sentences
Summary
Severe hypoglycemia occurred in one patient (MET + SU).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients from seven phase 3 AWARD [Assessment of Weekly AdministRation of LY2189265 (Dulaglutide) in Diabetes] trials, where once-weekly dulaglutide 1.5 mg was added to OHs, were pooled into the following categories based on OH regimens: metformin (MET), sulfonylurea (SU), MET + SU, MET + pioglitazo…
Report a problemFND-3160530209

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.